---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-012816"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T11:51:14.756217+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics Q2 cash $58M; uproleselan Phase 3 topline by Q2 2024; GMI-1687 Phase 1a in Q3

## Summary
- Cash $58.0M at June 30, 2023, up from $47.9M at Dec 31, 2022; R&D spend $4.1M, down 49% YoY.
- Pivotal Phase 3 uproleselan R/R AML topline results expected by end of Q2 2024 after time-based analysis amendment.
- FDA agreed to initial Pediatric Study Plan; NCI will sponsor Phase 1/2 uproleselan study in pediatric AML.
- First pediatric patient dosed in investigator-initiated Phase 1/2 study of uproleselan with pre-transplant conditioning.
- GMI-1687 (E-selectin antagonist) Phase 1a study in healthy volunteers to initiate in Q3 2023.

## SEC filing metadata
- accession: 0001558370-23-012816
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/0001558370-23-012816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/glyc-20230802x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-012816
- JSON: https://secwatch.observer/filing/0001558370-23-012816.json
- Plain text: https://secwatch.observer/filing/0001558370-23-012816.txt

## Key facts
- Earnings Releases
  CRESCENT BIOPHARMA, INC. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 2, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/0001558370-23-012816-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.